Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models-Reference-Cited by-同舟云学术

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Published:2019-08-22 Issue:1 Volume:38 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

Peng Xia,Hou Pengcong,Chen Yi,Dai Yang,Ji Yinchun,Shen Yanyan,Su Yi,Liu Bo,Wang Yueliang,Sun Deqiao,Jiang Yuchen,Zha Chuantao,Xie Zuoquan,Ding Jian,Geng Meiyu,Ai Jing

Funder

the Natural Science Foundation of China

“Personalized Medicines --Molecular Signature-based Drug Discovery and Development” Strategic Priority Research Program of the Chinese Academy of Sciences

Personalized Medicines --Molecular Signature-based Drug Discovery and Development” Strategic Priority Research Program of the Chinese Academy of Sciences

the Natural Science Foundation of China for Innovation Research Group

the National Science & Technology Major Project

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-019-1357-y.pdf

Reference51 articles.

1. Dutra RL, dos Santos M, Mendes SO, Peterle GT, Louro I'r D, da Silva Conforti AM A’l. FGFR4 as a biomarker in squamous cell cancers of mouth and oropharynx. In: Preedy VR, Patel VB, editors. Biomarkers in disease: Methods, Discoveries and Applications. London; 2015. p. 809–26. http://www.springer.com/series/13842 .

2. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.

3. Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in Cancer. Clin Cancer Res. 2015;21:2684–94.